Top Four Considerations For Tech Transfer Performance

By Lei Zheng, Biomedical Engineering, Pfizer CentreOne


A top priority for drug developers is to find outsourcing partners with experience in transferring and scaling their product formulation and processes from sending unit (SU) to commercial-scale receiving unit (RU) in compliance with regulatory agencies.

A successful manufacturing technology transfer is how long-term strategic CDMO relationships begin. A product’s continued success may hinge on this critical exchange of product data and range of regulatory filings required.

Whether you are a drug developer searching for a CDMO partner for the first time, rising to a new role, or a veteran scrambling to fill a gap in your supply chain, there are four key considerations for gauging strong technology transfer performance: geographic footprint, technology, regulatory compliance, and talent.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development